期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

NOD/SCID小鼠平台上的肿瘤实验研究进展 被引量：17

Progress of cancer experimental research in NOD/SCID mice
下载PDF
导出
摘要 非肥胖糖尿病/严重联合免疫缺陷(non-obese diabetes-SCID mice,NOD/SCID)小鼠具有T、B淋巴细胞联合免疫缺陷、NK细胞活性低下、无循环补体、巨噬细胞和抗原提呈细胞功能损害等特性,近年已成为人类肿瘤移植瘤的最佳研究模型。NOD/SCID鼠的人类血液系统肿瘤模型能够研究造血微环境、白血病细胞的分化调控机制和潜在的治疗靶点,并且建立在此平台上的体内药敏实验,可以指导临床化疗方案设计,目前已显示出突出的疗效。乳腺癌等实体瘤原代肿瘤组织的移植瘤模型,也显示出可复制人类肿瘤特点的优势。此外,NOD/SCID鼠可进行肿瘤干细胞的筛选和鉴定,并寻找针对肿瘤干细胞的特异性治疗靶点。目前的研究已展现了NOD/SCID鼠在肿瘤研究领域的广阔前景。 Non-obese diabetes-SCID mice （NOD/SCID） have not only immune function of T, B lymphocyte, but also circulation complement and microphage cells. Meanwhile, they have the characteristics of low activity of NK cells and damaged function of antigen presenting cells. Recently, this breed has become optimal xenograft model of human tumor. Human hematology tumor established in NOD/SCID mice could be investigated bematopoietic microenvironment, mechanism of differentiation and modulation of leukaemia cells and potential therapeutic targets. Besides, drug sensitivity experiments in vivo may instruct optimal chemotherapy projects. The primary cancer tissue xenograft model of solid tumor like breast cancer has showed the advantage of duplicating human cancer. In addition, researchers could filtrate and identify cancer stem cells by NOD/SCID mice, so the study of specific therapeutic targets of cancer progenitor cells is available. Now investigations have exhibited widely used of NOD/SCID mice in oncology.
作者 孙冰 吴世凯 宋三泰
机构地区 军事医学科学院附属三
出处 《中华肿瘤防治杂志》 CAS 2008年第4期307-310,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 肿瘤 小鼠 SCID 小鼠 近交NOD 综述文献 neoplasms mice, SCID mice, inbred NOD review literature
分类号 R73-3 [医药卫生—肿瘤]
  • 相关文献

参考文献27

  • 1Bosma G C, Custer R P, Bosma M J. A severe combined immunodeficiency mutation in the mouse [ J ]. Nature, 1983, 301(5900) : 527-530.
  • 2Dorshkind K, Keller G M, Phillips R A, et al. Functional status of cells from lymphoid and myeloid tissues in mice with severe combined ininnmodcficiency disease [J]. J Immunol, 1984, 132(4) : 1804- 1808.
  • 3Prochazka M, Gaskins H R, Shultz L D. The nonobese diabetic SCID mouse: model for spontaneous thymomagenesis associated with immunodeficiency[J]. Proc Natl Acad Sci U S A, 1992, 89(8) : 3290-3294.
  • 4Shultz L D, Schweitzer P A, Christianson S W, et al. Multiple defects of innate and adaptive immunologic function in NOD/ LtSz-scid mice[J]. J Immunol, 1995,15,1(1):180-191.
  • 5HesseltonR M , Greiner DL , MordesJ P , et al. High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/ LtSz2scid/ scid mice[J]. J Infect Dis, 1995, 172(4) : 974-982.
  • 6Feuring-Buske M, Gerhard B, Cashman J,et al. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2 microglobulin deficient NOD/SCID mice transgenic for human growth factors[J]. Leukemia, 2003, 17(4): 760-763.
  • 7Dazzi F, Capelli D, Hasserjian R, et al. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in nonobese diabetic severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology[J]. Blood, 1998, 92 (4) : 1390-1396.
  • 8Hauswirth A W, Florian S, Printz D, et al. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells[J]. Eur J Clin Invest,2007, 37(1):73-82.
  • 9Yilmaz O H , Valdez R , Theisen B K, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells[J]. Nature, 2006, 441(25): 475-482.
  • 10Fichtner I, Paal K. Chemo-and radiation sensitivity of xenografted acute lymphoblastic leukemias correlation to the expression of multidrug resistance proteins [ J ]. Anticancer Res, 2003, 23(3B) : 2657-2664.

二级参考文献35

  • 1Kyle RA.The role of high-dose chemotherapy in the treatment of multiple myeloma:a controversy.Ann Oncol,2000; 11 (Suppl 1):55 -58
  • 2Chiusolo P,Sica S,Piccirillo N,et al.Molecular and clinical following-up after stem cell transplantation for multiple myeloma.Ann Hematol,2001; 80:90-95
  • 3Gahrton G,Bjorkstrand B.Progress in haematopoietic stem cell transplantation for multiple myeloma.J Intern Med,2000; 248:185-201
  • 4Liu Q,Gazitt Y.Adenovirus-mediated delivery of p53 results in substantial apoptosis to myeloma cells and is not cytotoxic to flow-sorted CD34 + hematopoetic progenitor cells and normal lymphocytes.Exp Hematol,2000; 28:1354 - 1362
  • 5Trudel S,Li Z,Dodgson C,et al.Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma--a phase I study.Leukemia,2001; 15:846 -854
  • 6Tarte K,Zhang XG,Legouffe E,et al.Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumorspecific recognition by cytotoxic T cells.J Immunol,1999; 163:514- 524
  • 7Dotti G,Savoldo B,Yotnda P,et al.Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against,both CD40 + and CD40 - plasmacytoma cells.Blood,100:200 - 207
  • 8Gorschluter M,Ziske C,Glasmacher A,et al.Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma.Clin Canc Res,2001; 7:2195 -2204
  • 9Ruffini PA,Biragyn A,Kwak LW.Recent advances in multiple myeloma immunotherapy.Biomed Pharmacother,2002; 56:129 - 132
  • 10Hayashi T,Hideshima T,Akiyama M,et al.Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes.Blood,2003;102:1435 - 1442

共引文献2

同被引文献158

引证文献17

二级引证文献52

中华肿瘤防治杂志
2008年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部